
    
      The study will take place in Greece. Investigators will participate from a broad geographical
      distribution in order to ensure a proper representation from all areas of Greece.
      Investigator's decision to prescribe DMF (TecfideraÂ®) (according to the indication for
      treatment as defined in the summary of product characteristics, SmPC and the current clinical
      practice), should precede entry into the study.
    
  